Featured Research

from universities, journals, and other organizations

Pool Of Latently Infected, "Resting" Cells Established Early In HIV Infection

Date:
July 22, 1998
Source:
National Institute Of Allergy And Infectious Diseases
Summary:
Soon after the human immunodeficiency virus (HIV) enters a person's body, the virus sets up shop in resting (non-dividing) CD4+ T cells, according to researchers at the National Institute of Allergy and Infectious Diseases (NIAID).

Soon after the human immunodeficiency virus (HIV) enters a person's body, the virus sets up shop in resting (non-dividing) CD4+ T cells, according to researchers at the National Institute of Allergy and Infectious Diseases (NIAID).

The pool of latently infected immune system cells is established even if a patient is treated soon after acute infection with powerful antiretroviral drugs that reduce plasma levels of virus to extremely low or undetectable levels. Within the safe havens of resting CD4+ T cells, the virus may persist for years, despite highly active antiretroviral therapy (HAART), which is generally a combination of three drugs, including a protease inhibitor.

"Latent reservoirs of HIV, including resting CD4+ T cells, present a formidable obstacle to the ultimate control and possible eradication of HIV from an infected person's body," says Tae-Wook Chun, Ph.D., an investigator in NIAID's Laboratory of Immunoregulation (LIR).

Adds LIR Chief and NIAID Director Anthony S. Fauci, M.D., "Latently infected CD4+ T cells are potential sources of new viral replication if a patient stops therapy or is unable to adhere to the proper treatment regimen. We now know that these reservoirs are established very early in the course of infection." Dr. Fauci notes that "the establishment of the pool of latently infected, resting CD4+ T cells appears to occur around the time of the initial burst of virus replication seen in most patients with acute HIV infection."

Drs. Chun, Fauci and colleagues report their latest findings in the July 21, 1998, issue of the Proceedings of the National Academy of Sciences.

The investigators studied blood samples from 10 patients who were treated with the drugs zidovudine (AZT), lamivudine (3TC) and Crixivan (indinavir), soon after infection with HIV. Treatment was initiated between 10 days and 4.4 months following the initial onset of HIV-related symptoms. All of the patients responded positively to therapy, including five whose viral load fell to undetectable levels.

The LIR team found evidence of latently infected, resting CD4+ T cells in all 10 patients, even in an individual who had started HAART 10 days after the onset of the symptoms of acute HIV infection. Interestingly, the researchers found that neither duration of therapy nor the speed with which therapy was initiated correlated with the number of infected resting CD4+ T cells in a patient's blood. However, "The longest duration of therapy was 17 months, and it remains possible that an even longer duration of therapy with HAART, especially if initiated early in infection, may result in pronounced decreases in the pool of latently infected, resting CD4+ T cells," says Dr. Chun.

"A smaller pool of latently infected cells would be more likely to ultimately be controlled by the immune defenses of the patient," adds Dr. Fauci.

The NIAID investigators and others are pursuing studies to identify people recently exposed to HIV and to treat them before the viral burst, which probably disseminates the virus widely throughout the body. Such studies will help determine whether it is possible to prevent the early establishment of pools of latently infected, resting CD4+ T cells.

There are a number of potential approaches to containing or depleting reservoirs of latently infected, resting CD4+ T cells that have already been established in HIV-infected individuals. At the recent World AIDS Conference in Geneva, Dr. Fauci presented three possibilities: maintaining a strong immune system; enhancing a weakened immune system; and developing methods to deliberately purge the reservoirs by activating the resting cells to produce virus under the cover of HAART. Dr. Fauci's Geneva lecture is available on the World Wide Web at http://webcast.aids98.org (see plenary sessions for June 30, 1998).

Co-authors of Drs. Chun and Fauci include Delphine Engel of the LIR, and Drs. Lawrence Corey, M. Michelle Berrey and Theresa Shea of the University of Washington in Seattle.

NIAID is a component of the National Institutes of Health (NIH). NIAID conducts and supports research to prevent, diagnose and treat illnesses such as HIV disease and other sexually transmitted diseases, tuberculosis, malaria, asthma and allergies. NIH is an agency of the U.S. Department of Health and Human Services.

###

Press releases, fact sheets and other NIAID-related materials are available via the NIAID Web site at http://www.niaid.nih.gov.

Reference:Chun T-W, et al. Early establishment of a pool of latently infected, resting CD4+ T cells during primary HIV-1 infection. Proc Natl Acad Sci USA 1998;95(15):8869-73.


Story Source:

The above story is based on materials provided by National Institute Of Allergy And Infectious Diseases. Note: Materials may be edited for content and length.


Cite This Page:

National Institute Of Allergy And Infectious Diseases. "Pool Of Latently Infected, "Resting" Cells Established Early In HIV Infection." ScienceDaily. ScienceDaily, 22 July 1998. <www.sciencedaily.com/releases/1998/07/980722080515.htm>.
National Institute Of Allergy And Infectious Diseases. (1998, July 22). Pool Of Latently Infected, "Resting" Cells Established Early In HIV Infection. ScienceDaily. Retrieved September 18, 2014 from www.sciencedaily.com/releases/1998/07/980722080515.htm
National Institute Of Allergy And Infectious Diseases. "Pool Of Latently Infected, "Resting" Cells Established Early In HIV Infection." ScienceDaily. www.sciencedaily.com/releases/1998/07/980722080515.htm (accessed September 18, 2014).

Share This



More Health & Medicine News

Thursday, September 18, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Artificial Sweetener Could Promote Diabetes

Artificial Sweetener Could Promote Diabetes

Newsy (Sep. 17, 2014) Doctors once thought artificial sweeteners lacked the health risks of sugar, but a new study says they can impact blood sugar levels the same way. Video provided by Newsy
Powered by NewsLook.com
Ebola Vaccine Trial Gets Underway at Oxford University

Ebola Vaccine Trial Gets Underway at Oxford University

AFP (Sep. 17, 2014) A healthy British volunteer is to become the first person to receive a new vaccine for the Ebola virus after US President Barack Obama called for action against the epidemic and warned it was "spiralling out of control." Duration: 01:02 Video provided by AFP
Powered by NewsLook.com
Obesity Rates Steady Even As Americans' Waistlines Expand

Obesity Rates Steady Even As Americans' Waistlines Expand

Newsy (Sep. 17, 2014) Researchers are puzzled as to why obesity rates remain relatively stable as average waistlines continue to expand. Video provided by Newsy
Powered by NewsLook.com
President To Send 3,000 Military Personnel To Fight Ebola

President To Send 3,000 Military Personnel To Fight Ebola

Newsy (Sep. 16, 2014) President Obama is expected to send 3,000 troops to West Africa as part of the effort to contain Ebola's spread. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins